- Home
- NCNA vs KLTO Comparison
NCNA vs KLTO Comparison
Compare NCNA & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- KLTO
- Stock Information
- Founded
- NCNA 1997
- KLTO 2019
- Country
- NCNA United Kingdom
- KLTO United States
- Employees
- NCNA N/A
- KLTO N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- NCNA Health Care
- KLTO
- Exchange
- NCNA Nasdaq
- KLTO NYSE
- Market Cap
- NCNA 4.5M
- KLTO 5.0M
- IPO Year
- NCNA 2017
- KLTO N/A
- Fundamental
- Price
- NCNA $0.65
- KLTO $0.16
- Analyst Decision
- NCNA Buy
- KLTO
- Analyst Count
- NCNA 2
- KLTO 0
- Target Price
- NCNA $25.00
- KLTO N/A
- AVG Volume (30 Days)
- NCNA 140.2K
- KLTO 152.3K
- Earning Date
- NCNA 05-15-2025
- KLTO 05-15-2025
- Dividend Yield
- NCNA N/A
- KLTO N/A
- EPS Growth
- NCNA N/A
- KLTO N/A
- EPS
- NCNA N/A
- KLTO N/A
- Revenue
- NCNA N/A
- KLTO N/A
- Revenue This Year
- NCNA N/A
- KLTO N/A
- Revenue Next Year
- NCNA N/A
- KLTO N/A
- P/E Ratio
- NCNA N/A
- KLTO N/A
- Revenue Growth
- NCNA N/A
- KLTO N/A
- 52 Week Low
- NCNA $0.69
- KLTO $0.11
- 52 Week High
- NCNA $10.79
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- NCNA 39.85
- KLTO N/A
- Support Level
- NCNA $0.71
- KLTO N/A
- Resistance Level
- NCNA $0.89
- KLTO N/A
- Average True Range (ATR)
- NCNA 0.09
- KLTO 0.00
- MACD
- NCNA -0.00
- KLTO 0.00
- Stochastic Oscillator
- NCNA 12.68
- KLTO 0.00
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.